MXCT earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -3.05. Updated 2026-07-23.
MaxCyte (MXCT) Research Hub
MaxCyte (MXCT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.16 USD (-4.92%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.05, market cap 0.13B. This hub links to the full technical, earnings and options research available for MXCT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.16 USD (-4.92%) |
| 52-week range | 0.98 USD – 1.54 USD |
| Trend regime | Range |
| 14-day RSI | 48.6 (Neutral) |
| Trailing P/E | -3.05 |
| Market cap | 0.13B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for MXCT
Covered Call on MXCT: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MXCT: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MXCT: how it works, illustrative setup around the real 1.16 USD price, max profit/loss, breakeven and when to use it. Educational.
MXCT technical analysis: range, last 1.16 USD, RSI 48.6, 52w range 0.98 USD–1.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MXCT in?
MaxCyte (MXCT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MXCT in an uptrend or downtrend?
As of 2026-09-11, MXCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MXCT's trailing P/E ratio?
MXCT's trailing P/E is -3.05, with a market cap of 0.13B. See the earnings research page for full valuation detail.
When does MXCT next report earnings?
MXCT is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.12 USD.